dbacp02723
General Description
Peptide name : Dermaseptin-PS1
Source/Organism : Rock Kribensis Cichlid
Linear/Cyclic : Linear
Chirality : Not found
Sequence Information
Sequence : ALWKTMLKKLGTVALHAGKAALGAVADTISQ
Peptide length: 31
C-terminal modification: Linear
N-terminal modification : Not found
Non-natural peptide information: None
Activity Information
Assay type : Lactate dehydrogenase (LDH) assay, MTT cell proliferation assay
Assay time : 24h
Activity : MIC : 10−5 M and above
Cell line : U251MG
Cancer type : Human glioblastoma
Other activity : Anti-bacterial activity; Anti-microbial activity
Physicochemical Properties
Amino acid composition bar chart :
Molecular mass : 3164.7621 Dalton
Aliphatic index : 1.167
Instability index : 2.2484
Hydrophobicity (GRAVY) : 0.5032
Isoelectric point : 10.001
Charge (pH 7) : 2.8802
Aromaticity : 0.032
Molar extinction coefficient (cysteine, cystine): (5500, 5500)
Hydrophobic/hydrophilic ratio : 1.81818181
hydrophobic moment : -0.669
Missing amino acid : C,R,P,E,F,Y,N
Most occurring amino acid : A
Most occurring amino acid frequency : 7
Least occurring amino acid : W
Least occurring amino acid frequency : 1
Structural Information
3D structure :
Secondary structure fraction (Helix, Turn, Sheet): (0.5, 0.1, 0.3)
SMILES Notation: CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C(C)C)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)O
Secondary Structure :
| Method | Prediction |
|---|---|
| GOR | HHHHHHHHHHHHHHHHHHHHHHHHEEEHEEE |
| Chou-Fasman (CF) | CCHHHHHHEEEEHHHHHHHHHCCCEEEECCC |
| Neural Network (NN) | HHHHHHHHHHHHHHHHHHHHHHHHHHCCCCC |
| Joint/Consensus | HHHHHHHHHHHHHHHHHHHHHHHHEEECCCC |
Molecular Descriptors and ADMET Properties
Molecular Descriptors: Click here to download
ADMET Properties: Click here to download
Cross Referencing databases
CancerPPD : Not available
ApIAPDB : Not available
CancerPPD2 ID : Not available
Reference
1 : Long Q, et al. Novel peptide dermaseptin-PS1 exhibits anticancer activity via induction of intrinsic apoptosis signalling. J Cell Mol Med. 2019; 23:1300-1312. doi: 10.1111/jcmm.14032
Literature
Paper title : Novel peptide dermaseptin-PS1 exhibits anticancer activity via induction of intrinsic apoptosis signalling.
Doi : https://doi.org/10.1111/jcmm.14032
Abstract : Antimicrobial peptides (AMP) secreted by the granular glands of frog skin have been widely reported to exhibit strong bacteriostatic and bactericidal activities. Many of them have been documented with potent antiproliferative effects on multiple cancer cells, many studies also suggested that AMPs exert their functions via disrupting cell membranes. However, whether and how other cell death induction mechanism is involved in mammalian cancer cells has rarely been investigated. In this study, a novel AMP named Dermaseptin-PS1 was isolated and identified from Phyllomedusa sauvagei, it showed strong antimicrobial activities against three types of microorganisms. In vitro antiproliferative studies on human glioblastoma U-251 MG cells indicated that Dermaseptin-PS1 disrupted cell membranes at the concentrations of 10-5 M and above, while the cell membrane integrity was not affected when concentrations were decreased to 10-6 M or lower. Further examinations revealed that, at the relatively low concentration (10-6 M), Dermaseptin-PS1 induced apoptosis through mitochondrial-related signal pathway in U-251 MG cells. Thus, for the first time, we report a novel frog skin derived AMP with anticancer property by distinct mechanisms, which largely depends on its concentration. Together, our study provides new insights into the mechanism-illustrated drug design and the optimisation of dose control for cancer treatment in clinic.